MS: New Dosing, A New Withdrawal
Cutting the risk for natalizumab-related PML, update on disability outcomes with ibudilast, and daclizumab pulled from the global market.
Source: Medscape Pharmacists Podcast - Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts